Implementing the ESMO recommendations for the use of circulating tumor DNA (ctDNA) assays in routine clinical application/diagnostics

Liquid biopsy (LB) represents an advanced, minimally invasive approach that elevates the precision of oncological decision-making by identifying tumor DNA in bodily fluids. However, despite numerous endorsements from international specialty societies and working groups, implementation of LB into rou...

Full description

Bibliographic Details
Published in:Journal of Laboratory Medicine
Main Authors: Gamisch Alexander, Mustafa Hans Georg, Haushofer Alexander, Mustafa-Korninger Maria-Elisabeth
Format: Article
Language:English
Published: De Gruyter 2024-08-01
Subjects:
liquid biopsy
liquid profiling
molecular diagnostics
precision oncology
recommendations implementing test strategies
Online Access:https://doi.org/10.1515/labmed-2024-0029
Description
Summary:Liquid biopsy (LB) represents an advanced, minimally invasive approach that elevates the precision of oncological decision-making by identifying tumor DNA in bodily fluids. However, despite numerous endorsements from international specialty societies and working groups, implementation of LB into routine care is lagging behind due to conceptual and methodological uncertainties. This concise mini review aims to help catalyzing the translation of LB into routine care by exploring key considerations for incorporating circulating tumor DNA (ctDNA) analysis into clinical practice. Addressing eight pertinent questions from the perspective of a molecular oncology laboratory, this review synthesizes insights from the European Society for Medical Oncology (ESMO) recommendations and incorporates the latest findings from relevant literature, offering a comprehensive guide to the implementation of ctDNA assays.
ISSN:2567-9430
2567-9449

Similar Items